Familial Chylomicronemia Syndrome Market
Mar 27, 2023
Potential of APOCIII Inhibitors for Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome Treatment
Triglycerides, the energy-providing lipids consumed from fat-containing food, have been known to cause severe health conditions in high levels, including acute pancreatitis. It is also associated with apolipoprotein C-III (APOCIII) and high probability of coronary artery disease (CAD). Triglyceride levels above a c...
Read More...
Jul 24, 2020
Rejections and Withdrawals: Familial Chylomicronemia Syndrome Market Needs a Therapy sufficiently Effective, sufficiently Affordable
A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS) affects 1 in 1 to 2 million people (Burnett and Hegele, 1999; Pouwels et al. 2008). As per DelveInsight, the total Familial chylomicronemia syndrome diagnosed prevalent population in the 7MM [the US, EU4 (Germany, Franc...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
